Answers are grounded in this paper and cite their sources.
The contribution of ?3-AR activation towards ischemiareperfusion (IR) damage largely depends on the disease stage, severity, experimental model as well as drug specificities which should be considered when investigating ?3-AR pharmacology for potential therapeutic applications.
No takes yet. Share an insight, caveat, or question.
Salie et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: